RE: .045 on the bid. I agree that the silence is becoming deafening. It's been more than a month since the last NR. Hopefully, the 0.045 bids will shake Management into managing Investor relations again. I can't see Mr. Bryden being to happy with the potential to break through the 0.05 barrier.
The perplexing thing for me is that the NR really wasn't all that bad. "Statistical significance" simply means that there were not enough data points to assert that the results (even good ones) were not caused by chance. It would appear that the results also showed a need to improve the liposomal formulation: not necessarily surprising, since the liposomal approach was only conceived about 6 months ago. My main concern going forward is financing: not the product itself. Call me stupid (get in line), but I wonder if this is not an opportunity to tap some deep pockets (if they are out there), for tens of millions of new shares at around 5 cents. If we are to go forward, this dilution would have to happen eventually. The bargain basement price might attract a partner now. This would show stability going forward. If this product is to be ultimately successful, share prices in the 10 cents range would be in the rear view mirror.
Trading volumes are thankfully low. More than 99% of shareholders are holding firm. But I'm not sure how long this can last, given the likely nervousness of even long term holders (me included), caused by the lack of a stated plan going forward.
A month is long enough. What is the plan?